Literature DB >> 15517384

Sarcocystis neurona major surface antigen gene 1 (SAG1) shows evidence of having evolved under positive selection pressure.

Hany M Elsheikha1, Linda S Mansfield.   

Abstract

The major surface antigen gene 1 (SAG1) is conserved among members of Sarcocystidae and may play an important role in parasite pathogenesis. Additionally, generation and selection of different antigenic variants of SAG1 has the potential for inclusion in a subunit vaccine or in the development of a diagnostic assay. In this study, patterns of nucleotide polymorphism were used to test the hypothesis that natural selection promotes diversity in different parts of SAG1 of Sarcocystis neurona. Nucleotide and amino acid sequence analysis of SAG1 from multiple S. neurona isolates identified two alleles. Sequences were identical intra-allele and highly divergent inter-alleles. Also, phylogenetic reconstruction showed sequences clustering into two clades. Tajima's and Fu and Li's neutrality tests indicated that selection is more likely to be acting on SAG1. Moreover, a sliding window analysis based on the ratio of silent substitutions to amino acid replacements provided strong evidence that two short segments in the central and 3' domain of SAG1 have been under positive selection in the divergence of the two alleles, suggesting that it may be important for the evasion of host immune responses and would be a suitable target for vaccine development.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15517384     DOI: 10.1007/s00436-004-1237-y

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  23 in total

1.  DnaSP version 3: an integrated program for molecular population genetics and molecular evolution analysis.

Authors:  J Rozas; R Rozas
Journal:  Bioinformatics       Date:  1999-02       Impact factor: 6.937

Review 2.  Measuring immune selection.

Authors:  D J Conway; S D Polley
Journal:  Parasitology       Date:  2002       Impact factor: 3.234

3.  Seroprevalence of antibodies to Sarcocystis neurona in equids residing in Oklahoma.

Authors:  Bradford G Bentz; Katie A Ealey; Jennifer Morrow; P L Claypool; Jeremiah T Saliki
Journal:  J Vet Diagn Invest       Date:  2003-11       Impact factor: 1.279

4.  CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP.

Authors:  Joseph Felsenstein
Journal:  Evolution       Date:  1985-07       Impact factor: 3.694

5.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism.

Authors:  F Tajima
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

6.  Statistical tests of neutrality of mutations.

Authors:  Y X Fu; W H Li
Journal:  Genetics       Date:  1993-03       Impact factor: 4.562

7.  MEGA: Molecular Evolutionary Genetics Analysis software for microcomputers.

Authors:  S Kumar; K Tamura; M Nei
Journal:  Comput Appl Biosci       Date:  1994-04

8.  Inferring weak selection from patterns of polymorphism and divergence at "silent" sites in Drosophila DNA.

Authors:  H Akashi
Journal:  Genetics       Date:  1995-02       Impact factor: 4.562

9.  Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice.

Authors:  Valerie Letscher-Bru; Alexander W Pfaff; Ahmed Abou-Bacar; Denis Filisetti; Elisabeth Antoni; Odile Villard; Jean-Paul Klein; Ermanno Candolfi
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  A herd-level analysis of risk factors for antibodies to Sarcocystis neurona in Michigan equids.

Authors:  M G Rossano; J B Kaneene; J V Marteniuk; B D Banks; H C Schott; L S Mansfield
Journal:  Prev Vet Med       Date:  2003-02-15       Impact factor: 2.670

View more
  8 in total

1.  Patterns and role of diversifying selection in the evolution of Toxoplasma gondii SAG5 locus.

Authors:  Hany M Elsheikha; Xiangrong Zhao
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

Review 2.  An update on Sarcocystis neurona infections in animals and equine protozoal myeloencephalitis (EPM).

Authors:  J P Dubey; D K Howe; M Furr; W J Saville; A E Marsh; S M Reed; M E Grigg
Journal:  Vet Parasitol       Date:  2015-02-07       Impact factor: 2.738

3.  Molecular characterization of Sarcocystis neurona strains from opossums (Didelphis virginiana) and intermediate hosts from Central California.

Authors:  Daniel Rejmanek; Melissa A Miller; Michael E Grigg; Paul R Crosbie; Patricia A Conrad
Journal:  Vet Parasitol       Date:  2010-02-11       Impact factor: 2.738

4.  Genetic variation among isolates of Sarcocystis neurona, the agent of protozoal myeloencephalitis, as revealed by amplified fragment length polymorphism markers.

Authors:  H M Elsheikha; H C Schott; L S Mansfield
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

5.  Limited genetic diversity among Sarcocystis neurona strains infecting southern sea otters precludes distinction between marine and terrestrial isolates.

Authors:  J M Wendte; M A Miller; A K Nandra; S M Peat; P R Crosbie; P A Conrad; M E Grigg
Journal:  Vet Parasitol       Date:  2009-12-22       Impact factor: 2.738

6.  Enhancing in silico protein-based vaccine discovery for eukaryotic pathogens using predicted peptide-MHC binding and peptide conservation scores.

Authors:  Stephen J Goodswen; Paul J Kennedy; John T Ellis
Journal:  PLoS One       Date:  2014-12-29       Impact factor: 3.240

7.  The genome of the protozoan parasite Cystoisospora suis and a reverse vaccinology approach to identify vaccine candidates.

Authors:  Nicola Palmieri; Aruna Shrestha; Bärbel Ruttkowski; Tomas Beck; Claus Vogl; Fiona Tomley; Damer P Blake; Anja Joachim
Journal:  Int J Parasitol       Date:  2017-02-02       Impact factor: 3.981

8.  A Gene-Based Positive Selection Detection Approach to Identify Vaccine Candidates Using Toxoplasma gondii as a Test Case Protozoan Pathogen.

Authors:  Stephen J Goodswen; Paul J Kennedy; John T Ellis
Journal:  Front Genet       Date:  2018-08-20       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.